||This article needs more medical references for verification or relies too heavily on primary sources. (July 2012)|
|Classification and external resources|
Chemical structure of cystine formed from L-cysteine (under biological conditions)
Cystinuria is an autosomal recessive disease, which means that the defective gene responsible for the disease is located on an autosome, and two copies of the defective gene (one inherited from each parent) are required in order to be born with the disease. The parents of an individual with an autosomal recessive disease both carry one copy of the defective gene, but usually do not experience any signs or symptoms of the disease.
Cystinuria is caused by mutations in the SLC3A1 and SLC7A9 genes. These genes encode two parts of a transporter protein that is made primarily in the kidneys. These defects prevent proper reabsorption of basic, or positively charged, amino acids: lysine, ornithine, arginine. Under normal circumstances, this protein allows certain amino acids, including cysteine, to be reabsorbed into the blood from the filtered fluid that will become urine. Mutations in either of these genes disrupt the ability of this transporter protein to reabsorb these amino acids, allowing them to become concentrated in the urine. As the levels of cystine in the urine increase, the crystals typical of cystinuria are able to form, resulting in kidney stones. Cystine crystals form hexagonal-shaped crystals that can be viewed upon microscopic analysis of the urine. The other amino acids that are not reabsorbed do not create crystals in urine.
Cystinuria is characterized by the inadequate reabsorption of cystine in the proximal convoluted tubules after the filtering of the amino acids by the kidney's glomeruli, thus resulting in an excessive concentration of this amino acid in the urine. Cystine may precipitate out of the urine, if the urine is neutral or acidic, and form crystals or stones in the kidneys, ureters, or bladder. It is one of several inborn errors of metabolism included in the Garrod's tetrad. The disease is attributed to deficiency in transport and metabolism of amino acids.
Cystinuria is a cause of persistent kidney stones. It is a disease involving the defective transepithelial transport of cystine and dibasic amino acids in the kidney and intestine, and is one of many causes of kidney stones. If not treated properly, the disease could cause serious damage to the kidneys and surrounding organs, and in some rare cases death. The stones may be identified by a positive nitroprusside cyanide test. The crystals are usually hexagonal, translucent, white. Upon removal, the stones may be pink or yellow in color, but later they turn to greenish due to exposure to air. Cystinuria is usually asymptomatic when no stone is formed. However, once a stone is formed, or if stone production is severe or frequent, symptoms may be present:
- Dull ache or "colicky" pain
- Chronic pain
- Obstructive syndromes like hydronephrosis
- Infective syndromes like pyelonephritis
Cystinurics can also experience chronic pain in one, or both, kidneys due to the scars that the jagged edges of the stones can leave or damage from multiple stone removal surgeries. This can leave a cystinuric in constant pain which often requires medical intervention, such as long term use of analgesics or surgical procedures, including T11, T12 or T13 nerve blocks (although, these procedures are often not successful, they can provide some relief). Aside from the chronic pain, a cystinuric will often have severe breakthrough pain from passing stones. This type of severe pain, if not properly treated, will force the cystinuric to seek help in an Emergency Department or Urgent Care facility. Since most cystinurics pass stones monthly, weekly, or daily, and need ongoing care, this usually causes medical staff to label these patients as drug seekers or hypochondriacs. Cystinurics have an increased risk for chronic kidney disease and since kidney damage or poor function is often present in cystinurics, the use of nonsteroidal anti-inflammatory drugs (NSAIDs) or over the counter (OTC) medications should be used with caution. This leaves the patient with little choices regarding pain control and can lead to insufficient medical intervention by physicians.
Cystine stones are often not visible on most x-rays, CT's, and ultrasounds. This does not mean the cystinuric doesn't have a stone. It takes a trained eye and experience to spot a cystine stone. It is not unusual for a cystinuric to pass a stone, or stones, after being released from the hospital with a CT or x-ray result of no stones in the kidneys.
1. Blood: Routine hemogram along with blood sugar, urea, and creatinine.
2. Urine: For cystine crystals, and casts. The most specific test is the cyanide–nitroprusside test
3. Ultrasound/CT scan to reveal if a stone is present.
4. Genetic analysis to determine which mutation associated with the disease may be present. Currently genotyping is not available in the United States but might be available in Spain and Italy.
Regular X-rays often fail to show the cystine stones, however they can be visualized in the diagnostic procedure that is called intravenous pyelogram (or IVP for short). Stones may show up on XR with a fuzzy gray appearance. They are radioopaque due to sulfur content, though more difficult to visualize than calcium oxalate stones.
Initial treatment is with adequate hydration, alkalization of the urine with citrate supplementation or acetazolamide, and dietary modification to reduce salt and protein intake (especially methionine). If this fails then patients are usually started on chelation therapy with an agent such as penicillamine. Once renal stones have formed, however, the first-line treatment is ESWL (Extracorporeal shock wave lithotripsy). If ESWL do not work efficiently surgery can be necessary. Both endoscopic surgery and conventional open-abdominal surgery have proven to be effective treatment modalities for patients with more advanced disease.
Jeffrey Rimer of the University of Houston suggested in October 2010 that treatment with L-cystine dimethylester could prevent the formation of these kidney stones.
Videos of surgery are available on various websites that show stone removal by percutaneous nephrolithotomy.
Occurrence in animals
This disease is known to occur in at least three mammalian species: humans, domestic canines, and a wild canid, the Maned Wolf of South America. Cystine uroliths have been demonstrated, usually in male dogs, from approximately 70 breeds including the Australian cattle dog, Australian shepherd, Basenji, Basset, Bullmastiff, Chihuahua, Scottish deerhound, Scottish terrier, Staffordshire terrier, Welsh corgi, and both male and female Newfoundland dogs. 
- International Cystinuria Foundation
- Hartnup disease
- Medullary sponge kidney
- Fjellstedt, Erik; Harnevik, Lotta; Jeppsson, Jan-Olof; Tiselius, Hans-Göran; Söderkvist, Peter; Denneberg, Torsten (2003). "Urinary excretion of total cystine and the dibasic amino acids arginine, lysine and ornithine in relation to genetic findings in patients with cystinuria treated with sulfhydryl compounds". Urological Research 31 (6): 417–25. doi:10.1007/s00240-003-0366-6. PMID 14586528.
- Ahmed, K.; Dasgupta, P.; Khan, M. S. (2006). "Cystine calculi: Challenging group of stones". Postgraduate Medical Journal 82 (974): 799–801. doi:10.1136/pgmj.2005.044156. PMC 2653923. PMID 17148700.
- Online 'Mendelian Inheritance in Man' (OMIM) 220100
- http://cystinuria.com/symptoms/[unreliable medical source?]
- Sarica, Kemal; Yencilek, Faruk (2008). "Prevention of shockwave induced functional and morphological alterations: An overview". Archivio Italiano di Urologia e Andrologia 80 (1): 27–33. PMID 18533622.
- Rule, A. D.; Krambeck, A. E.; Lieske, J. C. (2011). "Chronic Kidney Disease in Kidney Stone Formers". Clinical Journal of the American Society of Nephrology 6 (8): 2069–75. doi:10.2215/CJN.10651110. PMC 3156433. PMID 21784825.
- Rule, A. D.; Bergstralh, E. J.; Melton, L. J.; Li, X.; Weaver, A. L.; Lieske, J. C. (2009). "Kidney Stones and the Risk for Chronic Kidney Disease". Clinical Journal of the American Society of Nephrology 4 (4): 804–11. doi:10.2215/CJN.05811108. PMC 2666438. PMID 19339425.
- http://cystinuria.com/diagnosis/[unreliable medical source?]
- Ahmed, Kamran; Khan, Mohammad Shamim; Thomas, Kay; Challacombe, Ben; Bultitude, Matthew; Glass, Jonathan; Tiptaft, Richard; Dasgupta, Prokar (2008). "Management of Cystinuric Patients: An Observational, Retrospective, Single-Centre Analysis". Urologia Internationalis 80 (2): 141–4. doi:10.1159/000112603. PMID 18362482.
- Joly, Dominique; Rieu, Philippe; méJean, Arnaud; Gagnadoux, Marie-France; Daudon, Michel; Jungers, P. (1999). "Treatment of cystinuria". Pediatric Nephrology 13 (9): 945–50. doi:10.1007/s004670050736. PMID 10603157.
- Rimer, J. D.; An, Z.; Zhu, Z.; Lee, M. H.; Goldfarb, D. S.; Wesson, J. A.; Ward, M. D. (2010). "Crystal Growth Inhibitors for the Prevention of L-Cystine Kidney Stones Through Molecular Design". Science 330 (6002): 337–41. doi:10.1126/science.1191968. PMID 20947757.
- D Bannasch and PS Henthorn (2009). "Changing Paradigms in Diagnosis of Inherited Defects Associated with Uroliths". Veterinary Clinics of North America. Small Animal Practice 39 (1): 111–125. doi:10.1016/j.cvsm.2008.09.006. PMC 2628803. PMID 19038654.